Opinions and Attitudes of Pulmonologists About Augmentation Therapy in Patients with Alpha-1 Antitrypsin Deficiency. A Survey of the EARCO Group

References

• Blanco I, Bueno P, Diego I, et al. Alpha-1 antitrypsin Pi*Z gene frequency and Pi*ZZ genotype numbers worldwide: an update. Int J Chron Obst Pulm Dis. 2017;12:561–569. doi:10.2147/COPD.S125389
   PubMed Web of Science ®Google Scholar
• Strnad P, McElvaney NG, Lomas DA. Alpha1-antitrypsin deficiency. N Engl J Med. 2020;382(15):1443–1455. doi:10.1056/NEJMra1910234
   PubMed Web of Science ®Google Scholar
• Blanco I, Diego I, Bueno P, Pérez-Holanda S, Casas-Maldonado F, Miravitlles M. Prevalence of alpha-1 antitrypsin genotypes in patients with COPD in Europe: a systematic review. Eur Respir Rev. 2020;29(157):200014. doi:10.1183/16000617.0014-2020
   PubMed Web of Science ®Google Scholar
• Wewers MD, Casolaro MA, Sellers SE, et al. Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. N Engl J Med. 1987;316(17):1055–1062. doi:10.1056/NEJM198704233161704
   PubMed Web of Science ®Google Scholar
• Stockley RA, Bayley DL, Unsal I, Dowson LJ. The effect of augmentation therapy on bronchial inflammation in alpha1-antitrypsin deficiency. Am J Respir Crit Care Med. 2002;165(11):1494–1498. doi:10.1164/rccm.2109013
   PubMed Web of Science ®Google Scholar
• Chapman KR, Burdon JG, Piitulainen E, et al. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;386(9991):360–368. doi:10.1016/S0140-6736(15)60860-1
   PubMed Web of Science ®Google Scholar
• American Thoracic Society. European Respiratory Society Statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2003;168:820–899.
   Web of Science ®Google Scholar
• Miravitlles M, Dirksen A, Ferrarotti I, et al. European Respiratory Society Statement: diagnosis and treatment of pulmonary disease in alpha-1 antitrypsin deficiency. Eur Respir J. 2017;50:1700610. doi:10.1183/13993003.00610-2017
   PubMed Web of Science ®Google Scholar
• Sandhaus RA, Turino G, Brantly ML, et al. The diagnosis and management of alpha-1 antitrypsin deficiency in the adult. Chronic Obstr Pulm Dis. 2016;3(3):668–682.
   PubMed Web of Science ®Google Scholar
• Demeo DL, Sandhaus RA, Barker AF, et al. Determinants of airflow obstruction in severe alpha-1-antitrypsin deficiency. Thorax. 2007;62(9):806–813. doi:10.1136/thx.2006.075846
   PubMed Web of Science ®Google Scholar
• Stockley RA, Edgar RG, Pillai A, Turner AM. Individualized lung function trends in alpha-1-antitrypsin deficiency: a need for patience in order to provide patient centered management? Int J Chron Obst Pulm Dis. 2016;11:1745–1756.
   PubMed Web of Science ®Google Scholar
• Esquinas C, Serreri S, Barrecheguren M, et al. Long-term evolution of lung function in individuals with alpha-1 antitrypsin deficiency from the Spanish registry (REDAAT). Int J Chron Obstruct Pulmon Dis. 2018;13:1001–1007. doi:10.2147/COPD.S155226
   PubMed Web of Science ®Google Scholar
• Tanash HA, Ekström M, Rönmark E, Lindberg A, Piitulainen E. Survival in individuals with severe alpha 1-antitrypsin deficiency (PiZZ) in comparison to a general population with known smoking habits. Eur Respir J. 2017;50(3):1700198. doi:10.1183/13993003.00198-2017
   PubMed Web of Science ®Google Scholar
• Stockley RA, Miravitlles M, Vogelmeier C. Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approach. Orphanet J Rare Dis. 2013;8:149. doi:10.1186/1750-1172-8-149
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Nuñez A, Torres-Durán M, et al. The importance of reference centers and registries for rare diseases: the example of Alpha-1 antitrypsin deficiency. COPD. 2020;17(4):346–354. doi:10.1080/15412555.2020.1795824
   PubMedGoogle Scholar
• Barrecheguren M, O’Hara K, Wilkens M, et al. Research Priorities in alpha-1 antitrypsin deficiency: results of a patients’ and healthcare providers’ international survey from the EARCO Clinical Research Collaboration. ERJ Open Res. 2020;6(4):00523–2020. doi:10.1183/23120541.00523-2020
   PubMedGoogle Scholar
• Miravitlles M, Chorostowska-Wynimko J, Ferrarotti I, et al. The European Alpha-1 Research Collaboration (EARCO): a new ERS Clinical Research Collaboration to promote research in alpha-1 antitrypsin deficiency. Eur Respir J. 2019;53(2):1900138. doi:10.1183/13993003.00138-2019
   PubMed Web of Science ®Google Scholar
• Casas F, Blanco I, Martínez MT, et al. Indications for active case searches and intravenous alpha-1 antitrypsin treatment for patients with alpha-1 antitrypsin deficiency chronic obstructive pulmonary disease: an update. Arch Bronconeumol. 2015;51:185–192. doi:10.1016/j.arbres.2014.05.008
   PubMed Web of Science ®Google Scholar
• Lopes AP, Mineiro MA, Costa F, et al. Portuguese consensus document for the management of alpha-1-antitrypsin deficiency. Pulmonology. 2018;24(Suppl 1):1–21. doi:10.1016/j.pulmoe.2018.09.004
   PubMedGoogle Scholar
• Attaway A, Majumdar U, Sandhaus RA, Nowacki AS, Stoller JK. An analysis of the degree of concordance among international guidelines regarding alpha-1 antitrypsin deficiency. Int J Chron Obstruct Pulmon Dis. 2019;14:2089–2101. doi:10.2147/COPD.S208591
   PubMed Web of Science ®Google Scholar
• Respreeza. Summary of product characteristics (SmPC). Available from: https://ec.europa.eu/health/documents/community-register/2015/20150820132594/dec_132594_es.pdf. Accessed July 11th, 2021.
   Google Scholar
• Prolastin. Summary of product characteristics (SmPC). Available from: http://grifols.com/documents/10192/27754341/ft-prolastin-es-en/786cce6a-effb-41b6-867f-59d7a34ca086. Accessed July 11th, 2021.
   Google Scholar
• Stockley JA, Stockley RA, Sapey E. There is no fast track to identify fast decliners in Alpha-1 antitrypsin deficiency by spirometry: a longitudinal study of repeated measurements. Int J Chron Obstruct Pulmon Dis. 2021;16:835–840. doi:10.2147/COPD.S298585
   PubMed Web of Science ®Google Scholar
• Horváth I, Canotilho M, Chlumský J, et al. Diagnosis and management of α1-antitrypsin deficiency in Europe: an expert survey. ERJ Open Res. 2019;5(1):00171–2018. doi:10.1183/23120541.00171-2018
   PubMedGoogle Scholar
• The Council of the European Union. Council recommendation of 8 June 2009 on an action in the field of rare diseases, 2009/C 151/02. Available from: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2009:151:0007:0010:EN:PDF. accessed July 11th, 2021.
   Google Scholar
• McElvaney GN, Sandhaus RA, Miravitlles M, et al. Clinical considerations in individuals with Alpha-1 Antitrypsin PI*SZ genotype. Eur Respir J. 2020;55(pii):1902410. doi:10.1183/13993003.02410-2019
   PubMed Web of Science ®Google Scholar
• Lara B, Miravitlles M. Spanish registry of patients with Alpha-1 antitrypsin deficiency; comparison of the characteristics of PISZ and PIZZ Individuals. COPD. 2015;12(Suppl 1):27–31. doi:10.3109/15412555.2015.1021912
   PubMedGoogle Scholar
• Green CE, Vayalapra S, Hampson JA, Mukherjee D, Stockley RA, Turner AM. PiSZ alpha-1 antitrypsin deficiency (AATD): pulmonary phenotype and prognosis relative to PiZZ AATD and PiMM COPD. Thorax. 2015;70(10):939–945.
   PubMed Web of Science ®Google Scholar
• Franciosi AN, Carroll TP, McElvaney NG. SZ alpha-1 antitrypsin deficiency and pulmonary disease: more like MZ, not like ZZ. Thorax. 2021;76(3):298–301. doi:10.1136/thoraxjnl-2020-215250
   PubMed Web of Science ®Google Scholar
• Sandhaus RA, Turino G, Stocks J, et al. alpha1-Antitrypsin augmentation therapy for PI*MZ heterozygotes: a cautionary note. Chest. 2008;134(4):831–834. doi:10.1378/chest.08-0868
   PubMed Web of Science ®Google Scholar
• Barjaktarevic I, Miravitlles M. Alpha-1 antitrypsin (AAT) augmentation therapy in individuals with the PI*MZ genotype: a pro/con debate on a working hypothesis. BMC Pulm Med. 2021;21(1):99. doi:10.1186/s12890-021-01466-x
   PubMed Web of Science ®Google Scholar
• Parr DG, Lara B. Clinical utility of alpha-1 proteinase inhibitor in the management of adult patients with severe alpha-1 antitrypsin deficiency: a review of the current literature. Drug Des Devel Ther. 2017;11:2149–2162. doi:10.2147/DDDT.S105207
   PubMed Web of Science ®Google Scholar